07:28 AM EDT, 10/24/2025 (MT Newswires) -- Eli Lilly's ( LLY ) Indian unit and Cipla announced on Thursday that they have signed a deal for the distribution and promotion of Eli Lilly's ( LLY ) tirzepatide drug for type 2 diabetes and weight management in India, under the brand name Yurpeak.

The deal grants Cipla the rights to distribute and promote Yurpeak in India, with the Eli Lilly ( LLY ) unit responsible for manufacturing and supplying the products, according to the statement. No financial details were disclosed.

The companies said Yurpeak will be priced the same as Mounjaro.